Opinion

Video

Future Perspectives in KRAS G12C-Mutated NSCLC

Author(s):

Joshua K. Sabari, MD,Edward B. Garon, MD, MS

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Noman Ashraf, MD, of Tampa General Hospital
October 24th 2024

2024 Regulatory Approvals Across NSCLC Propel the Therapeutic Landscape Forward

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

The OncFive
October 19th 2024

The OncFive: Top Oncology News and Trends for the Week of 10/13

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

Myung-Ju Ahn, MD, PhD, professor, hemato-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
October 16th 2024

Osimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLC

FDA
October 15th 2024

FDA Approves Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy